GlassScriptPhysician profile
Jamie Damico
NPI 1982062170
$17,384.25
in general payments reported to CMS, 2019-2025
57 companies · $3,508 in 2025
The $3,508 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,323 · 2022: $3,785 · 2023: $3,281 · 2024: $3,488 · 2025: $3,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $50.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,226.55 |
| Education | $50.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,648.79 | 2021-2025 | |
| Ucb, INC. | $1,203.32 | 2021-2025 | Zilbrysq, Briviact, Nayzilam |
| Acadia Pharmaceuticals INC | $1,192.92 | 2021-2025 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $1,094.29 | 2021-2025 | |
| Sk Life Science, INC. | $1,054.14 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $884.21 | 2021-2025 | Ultomiris, Soliris |
| Biogen, INC. | $717.98 | 2021-2025 | Vumerity, Tysabri |
| Pfizer INC. | $708.47 | 2023-2025 | |
| Lundbeck LLC | $644.48 | 2021-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $608.14 | 2021-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $512.53 | 2021-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $441.69 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Eisai INC. | $409.46 | 2021-2025 | |
| Horizon Therapeutics Plc | $400.24 | 2021-2023 | Uplizna |
| Lilly USA, LLC | $395.05 | 2021-2025 | Emgality, Amyvid, Kisunla |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Damico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.